Freeman Technology highlights relevance of the FT4 for DPI characterisation
Respiratory Drug Delivery (RDD) 2010, 25 - 29 April 2010, Florida, US
Dynamic powder characterization with the FT4 directly quantifies powder flowability and the response of a formulation to air, a critical property for successful DPI development. To ensure efficient drug delivery a DPI formulation/device combination must be engineered to achieve aerosolisation of the dose to a respirable size during use.
Research at the University of Bath has shown a robust correlation between FPD and aerated energy, a measure of how the flowability of the powder changes with the amount of air flowing through it. This makes the FT4 an extremely useful tool for the development of DPI formulations, which are required to disperse easily, with more consistent and less patient dependent performance.
The FT4 combines dynamic testing methodologies with shear and bulk property measurement, to provide comprehensive, process relevant powder characterisation. Precision engineering in combination with well-defined, automated test procedures deliver exceptional reproducibility and sensitivity. With application know-how that has been gained from 10 years working with industry, Freeman Technology also provides extensive powder processing expertise alongside the FT4 Powder Rheometer.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza